Mirikizumab for UC: Phase 3 Data Now Published in NEJM
Mirikizumab manufacturer Eli Lilly, which funded the study, is hoping the drug will become the first IL-23 inhibitor to be approved in the United States for the treatment of ulcerative colitis (UC).
MDedge News
source https://www.medscape.com/s/viewarticle/994319?src=rss
MDedge News
source https://www.medscape.com/s/viewarticle/994319?src=rss
Comments
Post a Comment